THE CLINICAL AND INTEGRATED MANAGEMENT OF COPD AN OFFICIAL DOCUMENT OF AIMAR (INTERDISCIPLINARY ASSOCIATION FOR RESEARCH IN LUNG DISEASE), AIPO (ITALIAN ASSOCIATION OF HOSPITAL PULMONOLOGISTS), SIMER (ITALIAN SOCIETY OF RESPIRATORY MEDICINE), SIMG (ITALIAN SOCIETY OF GENERAL MEDICINE)

被引:0
作者
Bettoncelli, G.
Blasi, F. [1 ]
Brusasco, V. [2 ]
Centanni, S. [3 ]
Corrado, A. [4 ]
De Benedetto, F. [5 ]
De Michele, F. [6 ]
Di Maria, G. U. [7 ,8 ]
Donner, C. F. [9 ]
Falcone, F. [10 ]
Mereu, C. [11 ,12 ]
Nardini, S. [13 ]
Pasqua, F. [14 ]
Polverino, M. [15 ]
Rossi, A. [16 ]
Sanguinetti, M. [17 ]
机构
[1] Univ Milan, Ca Granda Osped Maggiore Milano Fdn, Milan, Italy
[2] Univ Genua, Genoa, Italy
[3] Univ Milan, San Paolo Hosp, Milan, Italy
[4] Careggi Hosp, Florence, Italy
[5] SS Annunziata Hosp, Pneumol Unit, Chieti, Italy
[6] A Cardarelli Hosp, Pneumol & Resp Pathophysiol Unit 1, Naples, Italy
[7] Univ Catania, Pulmonol Unit, Sch Specializat Resp Dis, Catania, Italy
[8] Univ Catania, Dept Clin & Mol Biomed, Catania, Italy
[9] Mondo Med, Multidisciplinary & Rehabil Outpatient Clin, Borgomanero, NO, Italy
[10] Villalba & Villa Torri Hosp, GVM Care & Res, Dept Pneumol, I-40136 Bologna, Italy
[11] ASL 2, Dept Pneumol, Savona, SV, Italy
[12] ASL 2, Med Field Dept, Savona, SV, Italy
[13] Vittorio Veneto Gen Hosp ULS 7 Veneto Reg, Pulm & TB Unit, Vittorio Veneto, TV, Italy
[14] IRCCS S Raffaele, Rome, Italy
[15] ASL SA, North Salerno Lung Dis Pole, Salerno, Italy
[16] Univ & Gen Hosp Verona, Pneumol Unit, Verona, Italy
[17] San Filippo Neri Gen Hosp, Pneumol Unit UTIR, Rome, Italy
关键词
COPD; integrated care; management; OBSTRUCTIVE PULMONARY-DISEASE; AMERICAN THORACIC SOCIETY; FORMOTEROL DRY POWDER; AIR-FLOW OBSTRUCTION; SALMETEROL/FLUTICASONE PROPIONATE; BRONCHODILATOR THERAPY; ACUTE EXACERBATIONS; ACLIDINIUM BROMIDE; DOUBLE-BLIND; NONINVASIVE VENTILATION;
D O I
暂无
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
COPD is a chronic disease of the respiratory system characterized by persistent and partially reversible airflow obstruction, to which variably contribute remodeling of bronchi (chronic bronchitis), bronchioles (small airway disease) and lung parenchyma (pulmonary emphysema). COPD can cause important systemic effects and be associated with complications and comorbidities. the diagnosis of copd is based on the presence of respiratory symptoms and/or a history of exposure to risk factors, and the demonstration of airflow obstruction by spirometry. gard of Who has defined COPD "a preventable and treatable disease". the integration among general practitioner, chest physician as well as other specialists, whenever required, assures the best management of the COPD person, when specific targets to be achieved are well defined in a diagnostic and therapeutic route, previously designed and shared with appropriateness. the first-line pharmacologic treatment of copd is represented by inhaled long-acting bronchodilators. in patients with FeV1 < 60% of predicted and with a clinical history of proven bronchial hyperreactivity or with frequent exacerbations (>= 3/last 3 years) inhaled corticosteroid should be added. long term oxygen therapy (ltot) is indicated in stable patients, at rest while receiving the best possible treatment, and exhibiting a PaO2 = 55 mmhg (SO2 < 88%) or PaO2 values between 56 and 59 mmhg (SO2 < 89%) associated with pulmonary arterial hypertension, cor pulmonale, or edema of the lower limbs or hematocrit > 55%. respiratory rehabilitation is addressed to patients with chronic respiratory disease in all stages of severity who report symptoms and limitation of their daily activity. it must be integrated in an individual patient tailored treatment as it improves dyspnea, exercise performance, and quality of life. acute exacerbation of copd is a sudden worsening of usual symptoms in a person with copd, over and beyond normal daily variability that requires treatment modification. the pharmacologic therapy can be applied at home and includes the administration of drugs used during the stable phase by increasing the dose or modifying the route, and adding, whenever required, drugs as antibiotics or systemic corticosteroids. in case of patients who because of copd severity and/or of exacerbations do not respond promptly to treatment at home hospital admission should be considered. patients with "severe" or "very severe" copd who experience exacerbations should be carried out in respiratory unit, based on the severity of acute respiratory failure. an integrated system is required in the community in order to ensure adequate treatments also outside acute care hospital settings and rehabilitation centers.
引用
收藏
页码:3 / 21
页数:19
相关论文
共 137 条
  • [1] Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease - A randomized trial
    Aaron, Shawn D.
    Vandemheen, Katherine L.
    Fergusson, Dean
    Maltais, Francois
    Bourbeau, Jean
    Goldstein, Roger
    Balter, Meyer
    O'Donnell, Denis
    McIvor, Andrew
    Sharma, Sat
    Bishop, Graham
    Anthony, John
    Cowie, Robert
    Field, Stephen
    Hirsch, Andrew
    Hernandez, Paul
    Rivington, Robert
    Road, Jeremy
    Hoffstein, Victor
    Hodder, Richard
    Marciniuk, Darcy
    McCormack, David
    Fox, George
    Cox, Gerard
    Prins, Henry B.
    Ford, Gordon
    Bleskie, Dominique
    Doucette, Steve
    Mayers, Irvin
    Chapman, Kenneth
    Zamel, Noe
    FitzGerald, Mark
    [J]. ANNALS OF INTERNAL MEDICINE, 2007, 146 (08) : 545 - U15
  • [2] ALBERT RK, 1980, ANN INTERN MED, V92, P753, DOI 10.7326/0003-4819-92-6-753
  • [3] Andrew L.R., 2007, Pulmonary Rehabilitation, V131, P4
  • [4] [Anonymous], 1980, ANN INTERN MED, V93, P391
  • [5] [Anonymous], GLOB STRAT DIAGN MAN
  • [6] [Anonymous], EUR RESP J
  • [7] [Anonymous], 2004, RASSEGNA PATOLOGIA A
  • [8] [Anonymous], EUR RESP J
  • [9] [Anonymous], 2005, AM J RESP CRIT CARE
  • [10] [Anonymous], EUR RESP J